Saturday 17 October 2026
Export MLTX’s income statement to Excel — free account
MoonLake Immunotherapeutics
MLTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 3.45%, free cash flow fell 1.89% and total debt rose 35.6%, each against the same quarter a year earlier.
9.55
0.71
−6.92%
Follow MLTX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
9.27 | 21.11 | 51.59 | 9.98 | 0.46 | 12.93 | — |
Net Debt/EBITDA |
1.32 | 3.16 | 9.51 | 1.11 | (1.52) | 12.08 | — |
Debt/Assets |
17.46% | 0.00% | 0.00% | 0.17% | 154.92% | 0.05% | 0.00% |
Debt/Equity |
0.24 | 0.00 | 0.00 | 0.00 | (1.29) | (0.02) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.86 | 0.98 | 1.19 | 1.12 | 0.13 | 3.49 | — |
Capex/Depreciation |
(0.01) | (0.38) | (0.77) | (0.10) | 0.00 | — | — |
Interest Coverage |
(33.78) | — | — | — | (164.99) | (7.10) | — |
| (59.99%) | (24.60%) | (12.37%) | (175.19%) | 63.83% | (0.08%) | — | |
| (50.38%) | (23.68%) | (11.94%) | (115.51%) | (7.19%) | (0.16%) | — | |
ROIC |
0.00% | (1,667.26%) | (1,362.45%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(60.33%) | (26.28%) | (7.14%) | (72.54%) | 39.83% | (6.08%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Free Cash Flow per Share |
(3.04) | (1.86) | (0.88) | (1.90) | (0.21) | (0.11) | — |
Cash per Share |
6.11 | 7.13 | 10.40 | 2.46 | 2.80 | 0.46 | — |
Shareholders Equity per Share |
4.72 | 7.21 | 10.45 | 2.34 | (4.05) | (0.86) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
4.72 | 7.21 | 10.45 | 2.34 | (4.05) | (0.86) | — |
Free Cash Flow |
(196.04) | (117.11) | (43.06) | (55.91) | (0.61) | (0.32) | — |
Working Capital |
376.22 | 451.83 | 504.20 | 68.85 | (11.45) | 1.49 | — |
Capital Expenditures |
(0.03) | (0.52) | (0.28) | (0.02) | (0.05) | — | — |
Net Current Asset Value |
301.74 | 449.75 | 501.12 | 68.43 | (11.69) | (117.53) | — |
| Other line items | |||||||
Quick Ratio |
8.77 | 20.07 | 51.38 | 9.44 | 0.39 | 10.67 | — |
Depreciation/Fixed assets |
4.53 | 1.92 | 1.15 | 3.34 | 0.11 | — | — |
Cash ROIC |
(25.38%) | (12.99%) | (4.20%) | (39.65%) | (5.36%) | 28.22% | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(3.04) | (1.85) | (0.87) | (1.90) | (0.21) | (0.11) | — |
Capex per Share |
0.00 | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
3.86 | 1.95 | 0.64 | 0.18 | — | — | — |
Average Payables |
19.27 | 5.41 | 1.05 | 0.91 | 0.82 | — | — |
Average Assets |
451.18 | 502.24 | 301.69 | 43.26 | 63.16 | 58.32 | — |
Average Common Equity |
378.94 | 483.44 | 291.13 | 28.52 | (7.12) | 110.21 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Columns are period end dates